Amgen’s MCL-1 inhibitor, AMG 176, was also demonstrated to have preclinical activity across several hematological cancers as well as combination activity with traditional chemotherapeutics [14]. Here, MCL1 is linked to hematopoietic and lymphoid cell neoplasm.